Takeda Pharmaceutical Company Limited - SIC # 8740 -

Ticker Exchange SIC # Website Latest Ticker
TAK New York 8740 www.takeda.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Takeda Pharmaceutical Company Limited

Takeda (TAK) Q2 2025 Earnings Call Transcript - Feb 5th, 2026 12:55 pm
FRUZAQLA(TM) (fruquintinib capsules) now reimbursed in Ontario to treat metastatic colorectal cancer (mCRC) - Feb 2nd, 2026 6:00 am
Is Takeda’s Upgraded FY2025 Outlook And New PID Therapy Altering The Investment Case For Takeda (TSE:4502)? - Feb 2nd, 2026 1:10 am
Takeda Pharmaceutical (TSE:4502) Valuation Check After Recent Share Price Momentum And Mixed Fair Value Signals - Feb 1st, 2026 10:07 pm
Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Healthcare Stocks to Buy for 2026? - Jan 31st, 2026 7:36 am
H.C. Wainwright Sees Strength in Halozyme Therapeutics’ ENHANZE Platform, Reiterates Buy Rating - Jan 29th, 2026 1:00 pm
Takeda Pharmaceutical Q3 Earnings Call Highlights - Jan 29th, 2026 6:37 am
Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead - Jan 28th, 2026 11:37 pm
Halozyme Deepens ENHANZE Reach With Surf Bio Deal And Takeda Tie-Up - Jan 28th, 2026 11:07 am
Bleeding Disorders Treatment Global Market Review 2021-2025 and Forecast 2026-2031 Featuring Profiles of Takeda Pharmaceutical Co., Roche, Novo Nordisk, Pfizer, Bayer and More - Jan 28th, 2026 8:36 am
CMS selects next batch of 15 high-cost medicines for third negotiation cycle - Jan 28th, 2026 5:48 am
TD Cowen Notes Shifting Positive Sentiment for Halozyme (HALO) Ahead of Q4 Earnings, 2026 Guidance - Jan 22nd, 2026 7:52 pm
ADMA Gains 13.8% in Three Months: More Upside Potential for 2026? - Jan 22nd, 2026 7:13 am
Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1 - Jan 22nd, 2026 5:45 am
Assessing Takeda Pharmaceutical (TSE:4502) After Recent Pipeline Progress And Share Price Moves - Jan 21st, 2026 2:07 am
Halozyme (HALO) Boosted by ENHANZE Launches and Analyst Upgrade - Jan 20th, 2026 12:38 pm
JPM26: Matrix-M Technology is central to Novavax’s strategy - Jan 15th, 2026 4:19 pm
KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026? - Jan 15th, 2026 7:14 am
Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics - Jan 14th, 2026 7:00 am
Ascentage: Partnership With Takeda Going Well - Jan 13th, 2026 10:10 pm